Sisram Medical Ltd. provided earnings guidance for the year ending December 31, 2021. For the period, the company expects to record significant increases of more than 80% in its revenue for the Period and more than 120% in its profit for the Period, in each case, as compared to that for the corresponding period in 2020. The expected significant increases in revenue and profit for the Period are mainly attributable to the Group's global operation spanning across over 90 countries and regions worldwide, which facilitated the agility and mitigation of markets dynamics, strong position in its three leading markets: North America, China and Europe, with North America doubling its revenue year over year, and strong research and development capabilities, resulting in successful launch and commercialization of 5 new products over the past two years.